N-cyclobutyl-3-phenylpropionamide | 1142079-44-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-cyclobutyl-3-phenylpropionamide
• 英文别名: N-cyclobutyl-3-phenylpropanamide
• CAS: 1142079-44-4
• 化学式: C₁₃H₁₇NO
• mdl: MFCD24393093
• 分子量: 203.284
• InChiKey: YSWUXJTZFMVZIQ-UHFFFAOYSA-N

物化性质

• 熔点：
  109-110 °C(Solvent: Diethyl ether; Ligroine)
• 沸点：
  400.2±15.0 °C(predicted)
• 密度：
  1.06±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环丁基胺 、 3-苯丙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以82%的产率得到N-cyclobutyl-3-phenylpropionamide
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of N-(2-Oxo-3-oxetanyl)amides as N-Acylethanolamine-hydrolyzing Acid Amidase Inhibitors

  摘要：

  The fatty acid ethanolamides (FAEs) are a family of bioactive lipid mediators that include the endogenous agonist of peroxisome proliferator-activated receptor-alpha, palmitoylethanolamide (PEA). FAEs are hydrolyzed intracellularly by either fatty acid amide hydrolase or N-acylethanolamine-hydrolyzing acid amidase (NAAA). Selective inhibition of NAAA by (S)-N-(2-oxo-3-oxetanyl)-3-phenylpropionamide [(S)-OOPP, 7a] prevents PEA degradation in mouse leukocytes and attenuates responses to proinflammatory stimuli. Starting from the structure of 7a, a series of beta-lactones was prepared and tested on recombinant rat NAAA to explore structure-activity relationships (SARs) for this class of inhibitors and improve their in vitro potency. Following the hypothesis that these compounds inhibit NAAA by acylation of the catalytic cysteine, we identified several requirements for recognition at the active site and obtained new potent inhibitors. In particular, (S)-N-(2-oxo-3-oxetanyl)biphenyl-4-carboxamide (7h) was more potent than 7a at inhibiting recombinant rat NAAA activity (7a, IC(50) = 420 nM; 7h, IC(50) = 115 nM) in vitro and at reducing carrageenan-induced leukocyte infiltration in vivo.

  DOI：

  10.1021/jm100582w

文献信息

• Catalytic α-Hydroarylation of Acrylates and Acrylamides via an Interrupted Hydrodehalogenation Reaction
  作者：Alena M. Vasquez、John A. Gurak、Candice L. Joe、Emily C. Cherney、Keary M. Engle

  DOI：10.1021/jacs.0c03040

  日期：2020.6.10

  The palladium-catalyzed, α-selective hydroarylation of acrylates and acrylamides is reported. Under optimized conditions, this method is highly tolerant of a wide range of substrates including those with base sensitive functional groups and/or multiple enolizable carbonyl groups. A detailed mechanistic study was undertaken, and the high selectivity of this transformation was shown to be enabled by

  报道了钯催化的丙烯酸酯和丙烯酰胺的 α 选择性加氢芳基化。在优化条件下，该方法对多种底物具有高度耐受性，包括具有碱敏感官能团和/或多个可烯醇化羰基的底物。进行了详细的机理研究，表明这种转化的高选择性是通过形成 [PdII(Ar)(H)] 中间体实现的，该中间体将氢化物选择性插入 α 的 β 位， β-不饱和羰基化合物。
• COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE
  申请人：The Regents of the University of California

  公开号：US20160256432A1

  公开（公告）日：2016-09-08

  Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases.

  本文考虑研制抑制N-酰基-乙醇胺水解酸酶（NAAA）的化合物和药物组合物，以增加NAAA的底物棕榈酰乙醇胺（PEA）的浓度。考虑到NAAA的抑制是有效缓解与PEA浓度降低有关的疾病的条件。除其他用途外，各种NAAA抑制剂尤其被认为是治疗炎症性疾病的治疗剂。
• Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase
  申请人：The Regents of the University of California

  公开号：US10363237B2

  公开（公告）日：2019-07-30

  Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases.

  考虑使用抑制 N-酰基乙醇胺水解酸酰胺酶（NAAA）的化合物和药物组合物，以提高 NAAA 底物棕榈酰乙醇酰胺（PEA）的浓度。NAAA 抑制可有效缓解与 PEA 浓度降低有关的状况。除其他用途外，特别考虑将各种 NAAA 抑制剂作为治疗炎症性疾病的治疗剂。
• US9321743B2
  申请人：——

  公开号：US9321743B2

  公开（公告）日：2016-04-26